title: Relationship between fluorouracil systemic exposure and tumor response and patient survival.
abstract: OBJECTIVE
  The aim of this study was to analyze the link between fluorouracil (FU) systemic exposure and tumor response and overall survival.
  
  
  METHODS
  One hundred eighty-six patients (162 men, 24 women) with head and neck cancer were studied. All received cisplatin plus FU for three cycles as first-line chemotherapy. The treatment consisted of cisplatin (100 mg/m2 intravenously [IV]) followed by a 5-day continuous venous infusion of FU (1 g/m2/d). The median follow-up duration for the 104 patients alive was 24 months. For each cycle, we calculated the area under the curve over the duration of pharmacokinetic follow-up (AUC0-105 h) for plasma FU. For each patient, we analyzed the averaged AUC0-105 h and the averaged total dose for the three cycles.
  
  
  RESULTS
  The response rate was 30% complete responses (CRs), 22% partial responses (PRs) more than 75%, 25% PRs less than 75%, and 23% no response (NR). Medians for averaged AUC and dose per cycle were 27,906 ng/mL h (first through third quartile, 25,398 to 31,060) and 7,000 mg (first through third quartile, 6,200 to 7,833), respectively. The tumor response was significantly linked to tumor stage (P < .001) and to averaged AUC (P = .05), but not to averaged dose. Analysis of parameters (continuous variable) expressing FU treatment intensity showed that dose did not influence survival contrary to the AUC (P = .001). The AUC remains significant (P = .025) in a multivariate analysis including tumor stage, demonstrating that the greater the FU systemic exposure, the longer the survival.
  
  
  CONCLUSIONS
  These results strengthen the interest of individual FU dose adaptation based on pharmacokinetics.
authors.affiliation: Centre Antoine Lacassagne, Nice, France.
authors.forename: G
authors.initials: G
authors.lastname: Milano
authors.forename: M C
authors.initials: MC
authors.lastname: Etienne
authors.forename: N
authors.initials: N
authors.lastname: Renée
authors.forename: A
authors.initials: A
authors.lastname: Thyss
authors.forename: M
authors.initials: M
authors.lastname: Schneider
authors.forename: A
authors.initials: A
authors.lastname: Ramaioli
authors.forename: F
authors.initials: F
authors.lastname: Demard
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D002945:Cisplatin; D005472:Fluorouracil